Jan 18, 2024
In reference to the official press release of our pharma partner Ferrer, we regret to share that the top-line results of the phase 3 clinical study ADORE* show that the primary or key secondary endpoints were not met. In the ADORE study, our lead product TW001 (FAB122...
Nov 9, 2021
With the licensing agreement between Treeway and Ferrer in place, FNP122 (formerly TW001) has now entered clinical stage phase III with the initiation of the ADORE study (ALS Deceleration study with Oral Edaravone). In a large-scale double-blind placebo-controlled...
Oct 20, 2021
Barcelona and Tilburg, 20 October 2021 – Today, Ferrer, an international pharmaceutical company focused on pulmonary vascular and interstitial lung diseases and neurological disorders, and Treeway, a clinical-stage biotechnology company, announced they have entered...
Apr 10, 2019
On Thursday April 18, Treeway’s CEO Inez de Greef is a speaker at the Rare Diseases Symposium. The second edition of the Rare Disease Symposium, organized by HollandBIO, is about challenging the status quo and the development of orphan drugs. Inez will talk about...
Mar 21, 2018
This week, the Australian Motor Neurone Disease Symposium takes place in Melbourne, Australia. Our CEO, Inez de Greef-van der Sandt, will present the clinical development of TW001 by Treeway...
Mar 15, 2018
Op maandag 9 april wordt in samenwerking met het Jeroen Bosch Ziekenhuis een maatschappelijk symposium georganiseerd rondom het thema ALS. Vanuit drie invalshoeken zal het thema worden geduid. Inez de Greef, CEO van Treeway, zal spreken over de zoektocht naar een...
